AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03873766 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Protocol Image #2: Chest X-ray PA/Lateral
Description: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
Study NCT03873766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life
Description: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
Study NCT03707132 — intervention group
Intervention type: PROCEDURE
Intervention: Tourniquet: Folley catheter in the low segment of the uterus
Study NCT04436237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality foot placement training
Description: The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
Study NCT04436237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality foot placement training
Description: The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
Study NCT00754143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FG-3019
Description: Placebo every 2 weeks IV for all infusions
Study NCT00754143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 5 mg/kg every 2 weeks IV for all infusions
Study NCT00754143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
Study NCT01016964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb 2009 model 12 beam
Description: HairMax LaserComb
Study NCT01016964 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham Device
Study NCT03837314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioinduction Picostim Deep Brain Stimulation system
Description: Neurostimulation of the subthalamic nucleus region.
Study NCT01920594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
Study NCT01920594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
Study NCT03811639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency ablation
Description: Ablation for atrial fibrillation
Study NCT03811639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Ablation for atrial fibrillation
Study NCT02870569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib 200mg
Description: Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
Study NCT02870569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donafenib 300mg
Description: Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
Study NCT03903874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep south Interactive voice response system supported Active Lifestyle (DIAL)
Description: 12 months of automated telephone physical activity counseling with community health worker support
Study NCT00256334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
Study NCT02460497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment: Minoxidil 2% / Botanical Hair Solution for Women
Study NCT00597077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate vs rhythm control strategies for atrial fibrillation
Description: Rate vs rhythm control strategies for atrial fibrillation
Study NCT00597077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate vs rhythm control strategies in atrial fibrillation
Description: rate vs rhythm control strategies in atrial fibrillation
Study NCT02221986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation
Study NCT03305068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Study NCT02106754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Study NCT02106754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention with Coaching
Study NCT02106754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study NCT00420017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Intravenous amiodarone continuous infusion x 4 days
Study NCT00420017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No amiodarone
Study NCT03868969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin Oral Suspension
Description: Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
Study NCT02706301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Coping Skills Training (CST)
Study NCT03786978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical care
Description: Patients receive a structured pharmaceutical care from one year after basal hospital discharge
Study NCT03786978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Patient received a single phone call 30 days after basal hospital discharge.
Study NCT05794113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app - CanImmunize
Description: Using a mobile app
Study NCT05794113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Web based notification
Description: Using a web-based version of a survey
Study NCT01449877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
Study NCT01449877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
Study NCT02872077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Study NCT02619968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
Study NCT02619968 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: experimental group
Description: Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
Study NCT02598557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT02598557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02598557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02598557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study NCT02598557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02598557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02598557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT03431181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAP target 60-65 mmHg
Description: Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
Study NCT03431181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients in the control arm will receive usual care (as per local practices).
Study NCT02978534 — intervention group
Intervention type: DRUG
Intervention: Quetiapine
Description: Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
Study NCT02101450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
Study NCT02101450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
Study NCT02101450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: The cesarean incision will be sutured with no. 1 Vicryl ®.
Study NCT02101450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Description: Uterus will be replaced in the abdominal cavity.
Study NCT01351012 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn and safflower oil
Description: The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
Study NCT01351012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canola oil
Description: The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
Study NCT01351012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High oleic acid canola oil
Description: The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
Study NCT01351012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DHA enriched high oleic acid canola oil
Description: The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
Study NCT01351012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flax and safflower oil
Description: The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
Study NCT02072434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 30 mg tablets for oral administration
Study NCT02072434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin tablet, 1.0 or 2.5 mg, for oral administration
Study NCT02072434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin per label, at prescribed dose until PT INR at least 2.0
Study NCT01809535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
Study NCT01809535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
Study NCT01809535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
Study NCT01809535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wilson-Cook four shooter saeed multi-band ligator
Description: Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
Study NCT05013853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration teeth
Description: Remove caries and restore with resin composite
Study NCT05013853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration teeth
Description: Remove caries and restore with resin composite
Study NCT00619190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
Study NCT00765986 — intervention group
Intervention type: OTHER
Intervention: 18F-FAZA
Description: Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
Study NCT00765986 — intervention group
Intervention type: OTHER
Intervention: 18F-Fluorodeoxyglucose (18F-FDG)
Description: Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
Study NCT03157141 — intervention group
Intervention type: PROCEDURE
Intervention: Ankle arthrodesis
Description: Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
Study NCT03157141 — intervention group
Intervention type: PROCEDURE
Intervention: Total ankle replacement
Description: A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
Study NCT02604225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
Study NCT02604225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
Study NCT00257686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Study NCT00257686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study NCT00181584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Given intravenously once.
Study NCT00181584 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given intravenously once.
Study NCT04534933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evone
Description: Airway ventilation device
Study NCT04534933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primus
Description: Airway ventilation device
Study NCT03549000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NZV930
Description: NZV930, Specified dose on specified days, intravenous (IV)
Study NCT03549000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001, Specified dose on specified days, intravenous (IV)
Study NCT03549000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: NIR178 Specified dose on specified days, Orally
Study NCT02754882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Avastin® 15 mg/kg IV every 3 weeks on Day 1
Study NCT02754882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB8
Description: SB8 15 mg/kg IV every 3 weeks on Day 1
Study NCT02754882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT02754882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT02754882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT02754882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT02113241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
Study NCT02113241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 10 mg, one per day before breakfast during 90 days.
Study NCT03304353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-managed protocol
Description: Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
Study NCT03304353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Predetermined protocol
Description: Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards.
Study NCT04439071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: Oral tablets
Study NCT04439071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: As defined per local written policies or guidelines.
Study NCT04439071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: As defined per local written policies or guidelines.